Bayer aspirin MI petition
This article was originally published in The Tan Sheet
FDA should evaluate collected study data on aspirin for primary prevention of myocardial infarction "expeditiously," Bayer urges in Feb. 22 comments supporting the firm's petition to amend professional labeling to include the indication. The firm submitted data and protocols from five major prevention trials through Colin Baigent, MD, of Oxford's Clinical Trials Study Unit. Baigent previously presented a meta-analysis of the trials at a December 2003 meeting of the Cardiovascular & Renal Drugs Advisory Committee, convened to consider Bayer's petition (1"The Tan Sheet" Dec. 15, 2003, p. 4). The panel voted 11-3 against the new labeling, but the agency requested more information at an April 2004 feedback meeting...
You may also be interested in...
A long-term randomized prospective trial of at least 15,000 patients would be needed to adequately support professional aspirin labeling on primary prevention of myocardial infarction, according to members of FDA's Cardiovascular & Renal Drugs Advisory committee
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.